Sorrento takes over Sherrington’s drug candidate for chronic pain treatment – Pharmaceutical Business Review

by admin on October 11, 2013

Sorrento takes over Sherrington's drug candidate for chronic pain treatment
Pharmaceutical Business Review
US-based development-stage biopharmaceutical firm Sorrento Therapeutics has acquired Sherrington Pharmaceuticals (Sherrington), a company that provides chronic pain treatment for end-stage cancer patients and other severe pain indications. The drug 
Sorrento Therapeutics Acquires Clinical Stage Drug Candidate for Treatment of PR Newswire (press release)
Sorrento Therapeutics Buys Sherrington PharmaceuticalssocalTech.com

all 4 news articles »

View full post on chronic pain – Google News

Previous post:

Next post: